Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 47

1.

Osteoporotic bone formation in mice lacking tob2; involvement of Tob2 in RANK ligand expression and osteoclasts differentiation.

Ajima R, Akiyama T, Usui M, Yoneda M, Yoshida Y, Nakamura T, Minowa O, Noda M, Tanaka S, Noda T, Yamamoto T.

FEBS Lett. 2008 Apr 16;582(9):1313-8. doi: 10.1016/j.febslet.2008.03.012. Epub 2008 Mar 20.

2.

Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts.

Masuyama R, Stockmans I, Torrekens S, Van Looveren R, Maes C, Carmeliet P, Bouillon R, Carmeliet G.

J Clin Invest. 2006 Dec;116(12):3150-9. Epub 2006 Nov 9.

4.

Increased vitamin D-driven signalling and expression of the vitamin D receptor, MSX2, and RANKL in tooth resorption in cats.

Booij-Vrieling HE, Ferbus D, Tryfonidou MA, Riemers FM, Penning LC, Berdal A, Everts V, Hazewinkel HA.

Eur J Oral Sci. 2010 Feb;118(1):39-46. doi: 10.1111/j.1600-0722.2009.00707.x.

PMID:
20156263
5.

RANKL-induced schlafen2 is a positive regulator of osteoclastogenesis.

Lee NK, Choi HK, Yoo HJ, Shin J, Lee SY.

Cell Signal. 2008 Dec;20(12):2302-8. doi: 10.1016/j.cellsig.2008.08.019. Epub 2008 Aug 31.

PMID:
18796328
6.

Paeonol inhibits RANKL-induced osteoclastogenesis by inhibiting ERK, p38 and NF-kappaB pathway.

Tsai HY, Lin HY, Fong YC, Wu JB, Chen YF, Tsuzuki M, Tang CH.

Eur J Pharmacol. 2008 Jun 24;588(1):124-33. doi: 10.1016/j.ejphar.2008.04.024. Epub 2008 Apr 16.

PMID:
18495114
7.

Inhibitory immunoglobulin-like receptors LILRB and PIR-B negatively regulate osteoclast development.

Mori Y, Tsuji S, Inui M, Sakamoto Y, Endo S, Ito Y, Fujimura S, Koga T, Nakamura A, Takayanagi H, Itoi E, Takai T.

J Immunol. 2008 Oct 1;181(7):4742-51.

8.

TNF inhibits production of stromal cell-derived factor 1 by bone stromal cells and increases osteoclast precursor mobilization from bone marrow to peripheral blood.

Zhang Q, Guo R, Schwarz EM, Boyce BF, Xing L.

Arthritis Res Ther. 2008;10(2):R37. doi: 10.1186/ar2391. Epub 2008 Mar 27.

9.

The 4-1BB ligand and 4-1BB expressed on osteoclast precursors enhance RANKL-induced osteoclastogenesis via bi-directional signaling.

Yang J, Park OJ, Lee YJ, Jung HM, Woo KM, Choi Y.

Eur J Immunol. 2008 Jun;38(6):1598-609. doi: 10.1002/eji.200737650.

10.

Novel vitamin D3 analogs, 1alpha, 25(OH)2D(3)-26, 23-lactam (DLAMs), antagonize bone resorption via suppressing RANKL expression in osteoblasts.

Inada M, Tsukamoto K, Hirata M, Takita M, Nagasawa K, Miyaura C.

Biochem Biophys Res Commun. 2008 Aug 1;372(3):434-9. doi: 10.1016/j.bbrc.2008.05.041. Epub 2008 May 19.

PMID:
18489902
11.

Identification of NFAT binding sites that mediate stimulation of cathepsin K promoter activity by RANK ligand.

Balkan W, Martinez AF, Fernandez I, Rodriguez MA, Pang M, Troen BR.

Gene. 2009 Oct 15;446(2):90-8. doi: 10.1016/j.gene.2009.06.013. Epub 2009 Jun 27.

PMID:
19563866
12.

Zerumbone abolishes RANKL-induced NF-kappaB activation, inhibits osteoclastogenesis, and suppresses human breast cancer-induced bone loss in athymic nude mice.

Sung B, Murakami A, Oyajobi BO, Aggarwal BB.

Cancer Res. 2009 Feb 15;69(4):1477-84. doi: 10.1158/0008-5472.CAN-08-3249. Epub 2009 Feb 3.

13.

Receptor activator of nuclear factor-kappaB ligand-induced mouse osteoclast differentiation is associated with switching between NADPH oxidase homologues.

Sasaki H, Yamamoto H, Tominaga K, Masuda K, Kawai T, Teshima-Kondo S, Matsuno K, Yabe-Nishimura C, Rokutan K.

Free Radic Biol Med. 2009 Jul 15;47(2):189-99. doi: 10.1016/j.freeradbiomed.2009.04.025. Epub 2009 May 3.

PMID:
19409483
14.

The mechanism of osteoclast differentiation induced by IL-1.

Kim JH, Jin HM, Kim K, Song I, Youn BU, Matsuo K, Kim N.

J Immunol. 2009 Aug 1;183(3):1862-70. doi: 10.4049/jimmunol.0803007. Epub 2009 Jul 8.

15.

Msx2 -/- transgenic mice develop compound amelogenesis imperfecta, dentinogenesis imperfecta and periodental osteopetrosis.

Aïoub M, Lézot F, Molla M, Castaneda B, Robert B, Goubin G, Néfussi JR, Berdal A.

Bone. 2007 Nov;41(5):851-9. Epub 2007 Aug 15.

PMID:
17878071
16.

Bavachalcone inhibits osteoclast differentiation through suppression of NFATc1 induction by RANKL.

Park CK, Lee Y, Chang EJ, Lee MH, Yoon JH, Ryu JH, Kim HH.

Biochem Pharmacol. 2008 Jun 1;75(11):2175-82. doi: 10.1016/j.bcp.2008.03.007. Epub 2008 Mar 21.

PMID:
18433733
17.
18.

Deubiquitinating enzyme CYLD negatively regulates RANK signaling and osteoclastogenesis in mice.

Jin W, Chang M, Paul EM, Babu G, Lee AJ, Reiley W, Wright A, Zhang M, You J, Sun SC.

J Clin Invest. 2008 May;118(5):1858-66. doi: 10.1172/JCI34257.

19.

Identification of cell cycle-arrested quiescent osteoclast precursors in vivo.

Mizoguchi T, Muto A, Udagawa N, Arai A, Yamashita T, Hosoya A, Ninomiya T, Nakamura H, Yamamoto Y, Kinugawa S, Nakamura M, Nakamichi Y, Kobayashi Y, Nagasawa S, Oda K, Tanaka H, Tagaya M, Penninger JM, Ito M, Takahashi N.

J Cell Biol. 2009 Feb 23;184(4):541-54. doi: 10.1083/jcb.200806139.

20.

Risedronate directly inhibits osteoclast differentiation and inflammatory bone loss.

Kwak HB, Kim JY, Kim KJ, Choi MK, Kim JJ, Kim KM, Shin YI, Lee MS, Kim HS, Kim JW, Chun CH, Cho HJ, Hong GY, Juhng SK, Yoon KH, Park BH, Bae JM, Han JK, Oh J.

Biol Pharm Bull. 2009 Jul;32(7):1193-8.

Supplemental Content

Support Center